The Cellular Therapies Program at Smilow Cancer Hospital is led by Stuart Seropian, MD, Professor of Medicine (Hematology), Iris Isufi , MD, Associate Professor of Medicine (Hematology), and Michael Hurwitz, MD, PhD, Associate Professor of Medicine (Medical Oncology). Alex Dormal, RN, BSN, program manager, is available to assist with referrals and to help patients navigate their care. Together with their colleagues, they are leading clinical trials to advance the field of cellular therapies and discover additional treatment options for more types of cancer. This allows patients at Smilow Cancer Hospital some of the earliest access to novel cellular therapies and provides our team with exclusive experience delivering cellular therapies.
A comprehensive, multidisciplinary team is involved in the care of patients receiving these therapies, including a transplant team, a cell collection and processing unit, the Intensive Care Unit, pharmacy, social work, and access to telehealth for home evaluations. All patients are closely monitored for any side effects following therapy, and patients and families are given extensive education on how to safely continue care at home.
The Cellular Therapies Program at Smilow Cancer Hospital develops and delivers cell-based treatments to patients with cancer and other benign hematological diseases, including Chimeric Antigen Receptor T-Cell (CAR-T) Therapy, Tumor-Infiltrating Lymphocytes (TILs), and Gene Therapy. Current FDA-approved treatments available are:
CAR-T Therapy for Hematological Malignancies:
Large B-cell Lymphoma
Diffuse large B-cell Lymphoma
High-grade B-cell Lymphoma
Primary Mediastinal Large B-Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Refractory Follicular Lymphoma
Relapsed or Refractory Mantle Cell Lymphoma
Acute Lymphoblastic Leukemia
Multiple Myeloma
TIL Therapy for Solid Tumors:
Metastatic Melanoma
Gene Therapy Classical Hematology:
Sickle Cell Disease
B-Thalassemia